Bionano Genomics (NASDAQ:BNGO – Get Free Report) is projected to release its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect the company to post earnings of ($0.45) per share and revenue of $8.44 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.
Bionano Genomics (NASDAQ:BNGO – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.03. The company had revenue of ($6.67) million for the quarter, compared to analysts’ expectations of $7.55 million. Bionano Genomics had a negative return on equity of 78.78% and a negative net margin of 106.58%.
Bionano Genomics Price Performance
NASDAQ BNGO opened at $1.15 on Monday. The company has a market capitalization of $16.08 million, a PE ratio of -0.38 and a beta of 1.73. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.96 and a current ratio of 2.48. The business’s fifty day moving average is $1.37 and its 200 day moving average is $1.24. Bionano Genomics has a fifty-two week low of $1.00 and a fifty-two week high of $2.23.
Analyst Upgrades and Downgrades
BNGO has been the subject of a number of analyst reports. Weiss Ratings upgraded Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. Wall Street Zen raised Bionano Genomics to a “hold” rating in a research report on Saturday, September 26th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $6.00.
Check Out Our Latest Stock Analysis on BNGO
Bionano Genomics Company Profile
Bionano Genomics, Inc is a life sciences company that develops genomic analysis tools designed to help researchers and clinicians detect large-scale structural variations in DNA. Its technology is intended to complement or extend conventional sequencing and cytogenetic methods by providing information about changes in genome structure, including deletions, duplications, inversions and translocations.
The company’s principal platform is the Saphyr system, an optical genome mapping solution that analyzes ultra-high-molecular-weight DNA.
Read More
- Five stocks we like better than Bionano Genomics
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
